Mudit K. Jain, Phd

Inspire Medical Systems, Inc. has developed the world’s first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition.

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations

At Avivomed, we are focused on developing and commercializing next generation neuromodulaton technology platforms to treat patients suffering from chronic diseases.

ShiraTronics is working to develop new innovative therapies to combat debilitating chronic migraine headache. We are focused on commercializing novel neuromodulation technologies for this large unmet clinical need.